Cargando…

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?

Urothelial bladder cancer is one of the most lethal cancers worldwide with barely 5% five-year survival in patients with metastatic disease. Intravesical immunotherapy with Bacillus Calmette-Guérin and platinum-based chemotherapy are currently the standard of care for non-muscle invasive and advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roviello, Giandomenico, Catalano, Martina, Nobili, Stefania, Santi, Raffaella, Mini, Enrico, Nesi, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662285/ https://www.ncbi.nlm.nih.gov/pubmed/33114616 http://dx.doi.org/10.3390/ijms21217935

Ejemplares similares

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Inflammation in Urological Malignancies: The Silent Killer
por: Catalano, Martina, et al.
Publicado: (2023)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?
por: Houssiau, Hélène, et al.
Publicado: (2022)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy
por: Becattini, Lucrezia, et al.
Publicado: (2022)

Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Immune checkpoint inhibitors in ovarian cancer: where do we stand?
por: Leary, Alexandra, et al.
Publicado: (2021)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Where Do We Stand?
Publicado: (1891)

Cancer: Where We Stand
Publicado: (1951)

Ketogenic diet in the treatment of cancer – Where do we stand?
por: Weber, Daniela D., et al.
Publicado: (2019)

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
por: Franzin, Rossana, et al.
Publicado: (2020)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
por: Cosso, Federica, et al.
Publicado: (2023)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Neutrino Masses and Mixing: Where We Stand and Where We are Going
por: Gonzalez-Garcia, M.C.
Publicado: (2002)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Long Covid: where we stand and challenges ahead
por: Mantovani, Alberto, et al.
Publicado: (2022)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Where we stand with the real superworld
por: Zichichi, Antonino
Publicado: (1993)

Correcting LEP: where we stand
por: Kleiss, R H
Publicado: (1989)

Recurrent Glioblastoma: Where we stand
por: Roy, Sanjoy, et al.
Publicado: (2015)

Corneal xenotransplantation: Where are we standing?
por: Yoon, Chang Ho, et al.
Publicado: (2021)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Tumor-Associated Microbiome: Where Do We Stand?
por: Oliva, Marc, et al.
Publicado: (2021)

THREE-DIMENSIONAL PRINTING IN ORTHOPEDICS: WHERE WE STAND AND WHERE WE ARE HEADING
por: EJNISMAN, LEANDRO, et al.
Publicado: (2021)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Sympathetic Modulation in Cardiac Arrhythmias: Where We Stand and Where We Go
por: Chung, Wei-Hsin, et al.
Publicado: (2023)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3mhdtfdidvon8bg9tvj14dpdmf